ASCO 2022 Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment for HER2+ Gastric and GEJ Adenocarcinoma

130 views
June 17, 2022
Comments 0
Login to view comments. Click here to Login